They expect the Company to discuss with FDA the potential acceptability of an NDA filing in the NTM setting with the positive Phase III CF results as supportive. ...(and) estimate that ARIKACE represents at least a $300-million worldwide opportunity for the management of chronic Pa infections in patients with CF. .... A brief once-daily administration schedule and comparable efficacy to the market leader will in our opinion make ARIKACE the market-leading inhaled antibiotic in the CF setting. Reiterate Outperform.
Ahhh! Wedbush who's calls have been 100% contrarian! - every one...from the $15 !! just days before the rat data debacle...we now know the results were not "compelling" as Will Lewis had hoped. We know the company is looking for a "path to approval" and has dropped the mention of a filing in the U.S.
For traders - take advantage of the CYA from Wedbush